Erratum to "Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan" [ Kidney International Reports Volume 10, Issue 4, April 2025, Pages 1063-1075]

Affiliations

¹ Department of Nephrology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
² Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan.
³ Division of Endocrinology, Metabolism and Nephrology Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
⁴ Department of Nephrology, Tokyo Shinagawa Hospital, Tokyo, Japan.
⁵ Department of Nephrology, International University of Health and Welfare Atami Hospital, Shizuoka, Japan.
⁶ Department of Nephrology, International University of Health and Welfare Hospital, Tochigi, Japan.
⁷ Division of Nephrology, Shimane University Hospital, Shimane, Japan.
⁸ Department of Nephrology, Kawakita General Hospital, Tokyo, Japan.

Published Erratum

Kiyotaka Uchiyama et al. Kidney Int Rep. 2025.

. 2025 May 16;10(7):2505-2506.

doi: 10.1016/j.ekir.2025.05.025. eCollection 2025 Jul.

¹ Department of Nephrology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
² Department of Nephrology, Japanese Red Cross Medical Center, Tokyo, Japan.
³ Division of Endocrinology, Metabolism and Nephrology Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
⁴ Department of Nephrology, Tokyo Shinagawa Hospital, Tokyo, Japan.
⁵ Department of Nephrology, International University of Health and Welfare Atami Hospital, Shizuoka, Japan.
⁶ Department of Nephrology, International University of Health and Welfare Hospital, Tochigi, Japan.
⁷ Division of Nephrology, Shimane University Hospital, Shimane, Japan.
⁸ Department of Nephrology, Kawakita General Hospital, Tokyo, Japan.

Abstract

[This corrects the article DOI: 10.1016/j.ekir.2025.01.023.].

Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.
Uchiyama K, Kamano D, Nagasaka T, Hama EY, Shirai R, Sumura R, Kusahana E, Yanai A, Nakayama T, Kimura T, Takahashi R, Kasai T, Tajima T, Hosoya K, Azegami T, Yamaguchi S, Yoshino J, Ito J, Hayashi M, Kanda T, Ishibashi Y, Washida N, Itoh H, Hayashi K. Uchiyama K, et al. Kidney Int Rep. 2025 Jan 18;10(4):1063-1075. doi: 10.1016/j.ekir.2025.01.023. eCollection 2025 Apr. Kidney Int Rep. 2025. PMID: 40303212 Free PMC article.